Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure
oleh: Sarah M. Bahr, Benjamin J. Weidemann, Ana N. Castro, John W. Walsh, Orlando deLeon, Colin M.L. Burnett, Nicole A. Pearson, Daryl J. Murry, Justin L. Grobe, John R. Kirby
Format: | Article |
---|---|
Diterbitkan: | Elsevier 2015-11-01 |
Deskripsi
Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day) exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.